Lucille van Beek

Mrs. Lucille van Beek

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2020 in Virulence
Verified
Journal Article
Open access
LBLucille van Beek
Lucille van Beek
KSKristin Surmann
Kristin Surmann
HSH. Bart van Den Berg van Saparoea
H. Bart van Den Berg van Saparoea
DHDiane Houben
Diane Houben
WJWouter S. P. Jong
Wouter S. P. Jong
MJMarien I. de Jonge
Marien I. de Jonge
Nasopharyngeal colonization by Streptococcus pneumoniae is a prerequisite for pneumococcal transmission and disease. Current vaccines protect only against disease and colonization caused by a limited number of serotypes, consequently allowing serotype replacement and transmission. Therefore, the development of a broadly protective vaccine against colonization, transmission and disease is desired but requires a better understanding of pneumococcal adaptation to its natural niche. Hence, we measured the levels of free and protein-bound transition metals in human nasal fluid, to determine the effect of metal concentrations on the growth and proteome of S. pneumoniae. Pneumococci cultured in medium containing metal levels comparable to nasal fluid showed a highly distinct proteomic profile compared to standard culture conditions, including the increased abundance of nine conserved, putative surface-exposed proteins. AliA, an oligopeptide binding protein, was identified as the strongest protective antigen, demonstrated by the significantly reduced bacterial load in a murine colonization and a lethal mouse pneumonia model, highlighting its potential as vaccine antigen.

17 June 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
FVFranziska Voß
Franziska Voß
LBLucille van Beek
Lucille van Beek
DSDomini Schwudke
Domini Schwudke
TEThomas H. A. Ederveen
Thomas H. A. Ederveen
FOFred J. van Opzeeland
Fred J. van Opzeeland
Sven HammerschmidtSven Hammerschmidt
Sven Hammerschmidt
Streptococcus pneumoniae infections lead to high morbidity and mortality rates worldwide. Pneumococcal polysaccharide conjugate vaccines significantly reduce the burden of disease but have a limited range of protection, which encourages the development of a broadly protective protein-based alternative. We and others have shown that immunization with pneumococcal lipoproteins that lack the lipid anchor protects against colonization. Since immunity against S. pneumoniae is mediated through Toll-like receptor 2 signaling induced by lipidated proteins, we investigated the effects of a lipid modification on the induced immune responses in either intranasally or subcutaneously vaccinated mice. Here, we demonstrate that lipidation of recombinant lipoproteins DacB and PnrA strongly improves their immunogenicity. Mice immunized with lipidated proteins showed enhanced antibody concentrations and different induction kinetics. The induced humoral immune response was modulated by lipidation, indicated by increased IgG2/IgG1 subclass ratios related to Th1-type immunity. In a mouse model of colonization, immunization with lipidated antigens led to a moderate but consistent reduction of pneumococcal colonization as compared to the non-lipidated proteins, indicating that protein lipidation can improve the protective capacity of the coupled antigen. Thus, protein lipidation represents a promising approach for the development of a serotype-independent pneumococcal vaccine.

1 November 2021 in Vaccine
Verified
Journal Article
Open access
LBLucille van Beek
Lucille van Beek
JLJeroen D. Langereis
Jeroen D. Langereis
HSH.B. van Den Berg van Saparoea
H.B. van Den Berg van Saparoea
JGJ. Gillard
J. Gillard
WJW.S.P. Jong
W.S.P. Jong
MJM.I. de Jonge
M.I. de Jonge
Protein bodies (PBs) are particles consisting of insoluble, aggregated proteins with potential as a vaccine formulation. PBs can contain high concentrations of antigen, are stable and relatively resistant to proteases, release antigen slowly and are cost-effective to manufacture. Yet, the capacity of PBs to provoke immune responses and protection in the upper respiratory tract, a major entry route of respiratory pathogens, is largely unknown. In this study, we vaccinated mice intranasally with PBs comprising antigens from Streptococcus pneumoniae and evaluated the level of protection against nasopharyngeal colonization. PBs composed of the α-helical domain of pneumococcal surface protein A (PspAα) provided superior protection against colonization with S. pneumoniae compared to soluble PspAα. Immunization with soluble protein or PBs induced differences in antibody binding to pneumococci as well as a highly distinct antigen-specific nasal cytokine profile upon in vivo stimulation with inactivated S. pneumoniae. Moreover, immunization with PBs composed of conserved putative pneumococcal antigens reduced colonization by S. pneumoniae in mice, both as a single- and as a multi-antigen formulation. In conclusion, PBs represent a vaccine formulation that elicits strong mucosal immune responses and protection. The versatility of this platform offers opportunities for development of next-generation vaccine formulations.

23 September 2021 in Biomacromolecules
Verified
Journal Article
Open access
LBLucille van Beek
Lucille van Beek
PWPascal L. W. Welzen
Pascal L. W. Welzen
LTLisa U. Teufel
Lisa U. Teufel
IJIrma Joosten
Irma Joosten
DDDimitri A. Diavatopoulos
Dimitri A. Diavatopoulos
MJMarien I. de Jonge
Marien I. de Jonge
The use of well-defined nanovesicles composed of amphiphilic block copolymers (polymersomes) for delivery of adjuvants and antigens is a promising strategy for vaccine development. However, the potency of nanoparticle vaccines depends on efficient interaction with and activation of cells involved in antigen presentation, which can be achieved by targeting cellular receptors. Here, we showed that the Fc fragment display on the polymersome surface resulted in markedly improved interactions with granulocytes, monocytes, and NK cells, while for “naked” polymersomes, virtually no binding to leukocytes was observed. Moreover, CpG-decorated polymersomes were found to also interact with T and/or B cells. Interestingly, whole blood stimulations with Fc fragment and CpG-decorated polymersomes induced interleukin (IL)-6, IL-8, and TNF-α production, while naked polymersomes did not induce any cytokine production. In conclusion, specific immune induction by polymersomes can be controlled using bimodal targeting of different immune receptors, which is an essential feature for targeted vaccine delivery.

26 November 2022 in Vaccine
Verified
Journal Article
Open access
RURienke F. Uijen
Rienke F. Uijen
LBLucille van Beek
Lucille van Beek
FOFred van Opzeeland
Fred van Opzeeland
ESElles Simonetti
Elles Simonetti
SSSaskia van Selm
Saskia van Selm
MJMarien I. de Jonge
Marien I. de Jonge
Several studies have shown that intradermal vaccination leads to improved immune responses. In addition, lowering vaccine doses will reduce costs and therefore potentially increase coverage. To determine whether intradermal delivery enhances the antibody responses against the 13-valent pneumococcal conjugate vaccine (PCV13), we compared intradermally and intramuscularly vaccinated mice. Mice were immunized with PCV13, either intradermally or intramuscularly and CFU-counts in the nasal tissue were determined three or seven days after intranasal colonization with a serotype 4 clinical strain. Antibody concentrations against all thirteen polysaccharides were measured in blood and mucosal samples using a fluorescent-bead-based multiplex immunoassay. Antibody levels in both serum and mucosal samples were higher in the intramuscularly vaccinated group as compared to the intradermally vaccinated group. No protection against S. pneumoniae intranasal colonization was observed for either vaccination route. Intradermal vaccination was inferior to intramuscular immunization in inducing serotype-specific antibodies.

18 February 2026 in Journal of Infection
Verified
Journal Article
Open access
LBLucille van Beek
Lucille van Beek
SCSuzanne E.T. Comans
Suzanne E.T. Comans
KTKoen Totté
Koen Totté
JFJaneri Fröberg
Janeri Fröberg
CJChrista E. van der Gaast-De Jongh
Christa E. van der Gaast-De Jongh
DDDimitri A. Diavatopoulos
Dimitri A. Diavatopoulos
Colonisation of the upper airways by Streptococcus pneumoniae is a prerequisite for disease development and shapes immune responses that vary between geographical settings. This first controlled human pneumococcal infection study in the Netherlands assessed colonisation, antibody responses, respiratory symptoms, and concurrent viral infections. Twenty healthy adults (19-47 years) were enrolled between May 2022 and February 2023 and inoculated intranasally with 160,000 colony forming units of S. pneumoniae serotype 6B (strain BHN418). Participants were monitored for 28 days to assess colonisation, respiratory viral infection and safety. Serum and nasal lining fluid were collected to measure IgA, IgM and IgG responses to serotype 6B polysaccharide (6B) and whole pneumococci. Eight of 20 participants (40%) became colonised. Colonised participants showed significant rises in serum and mucosal IgG and IgA to 6B, but not to pneumococci. Fifteen participants tested positive for at least one respiratory virus. Symptoms were generally mild but occurred more often in those with concurrent pneumococcal colonisation and viral infection. Colonisation rates were comparable to studies in other populations. Colonisation induced systemic and mucosal antibody responses, while viral co-infection increased symptom burden. This controlled infection study demonstrates feasibility and safety, and establishes a platform for vaccine evaluation and pneumococcal-viral interaction studies.